Skip to main content
. Author manuscript; available in PMC: 2021 Aug 18.
Published in final edited form as: Vaccine. 2016 Oct 27;34(48):5886–5894. doi: 10.1016/j.vaccine.2016.10.036

Figure 2:

Figure 2:

IgG Subtype Quantification against recombinant HIV-1BaL gp120 (Env) (A) Quantitative ELISA of IgG1 Env specific antibodies from individual mouse sera at 0, 8, 12, and 16 weeks after immunization with VLPs and the indicated adjuvants (n = 10). (B) Quantitative ELISA of IgG2b Env specific antibodies from individual mouse sera at 0, 8, 12, and 16 weeks after immunization with VLPs and the indicated adjuvants (n = 10). (C) Quantitative ELISA of IgG2c Env specific antibodies from individual mouse sera at 0, 8, 12, and 16 weeks after immunization with VLPs and the indicated adjuvants (n = 10). (D) Quantitative ELISA of IgG3 Env specific antibodies from pooled mouse sera at 0, 8, 12, and 16 weeks after immunization with VLPs and the indicated adjuvants (n = 5). * indicates p <0.05 by 2-Way ANOVA and Bonferroni posttest when compared to PBS control. # indicates p < 0.05 by 2-Way ANOVA and Bonferroni posttest when compared to all other groups.